GHRL and metabolic dysfunction-associated steatotic liver disease: In contrast with the protective effect of ghrelin on the liver with inducible NAFLD, studies in non-obese animals (lean rats fed on standard diet) have shown that administration of exogenous AG carries a high risk of developing steatohepatitis and hepatic IR, while the addition of a balanced dose of UnAG reduces this risk, inhibits hepatic lipid accumulation, and enhances hepatic insulin signaling.